The Effects of Dopamine on Reward Processing
The purpose of this study is to evaluate the effects of a single low dose of the D2/D3 antagonist amisulpride on reward processing. More generally, this study will test the role of dopamine (a naturally occurring brain chemical) in depression.
Administration of a single low dose of the D2/D3 antagonist amisulpride will (1) improve performance in a behavioral task assessing learning from feedback and (2) boost activation in reward-related brain regions.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||The Effects of Dopamine on Reward Processing|
- Performance on a behavioral task assessing learning from positive and negative feedback. [ Time Frame: one-time task, administered during session 2 ] [ Designated as safety issue: No ]
- Brain activation during a task involving monetary rewards. [ Time Frame: one-time task, administered at session 2 ] [ Designated as safety issue: No ]
- Brain activation to social positive and negative feedback [ Time Frame: second session ] [ Designated as safety issue: No ]Brain activation to social positive and negative feedback
- Ratings of mood and affect. [ Time Frame: administered at sessions 1 and 2 ] [ Designated as safety issue: No ]
|Study Start Date:||February 2012|
|Estimated Study Completion Date:||February 2016|
|Estimated Primary Completion Date:||February 2016 (Final data collection date for primary outcome measure)|
Active Comparator: Amisulpride
single low-dose pharmacological challenge, 50 mg amisulpride capsule
single low-dose pharmacological challenge, 50 mg amisulpride
Other Name: Solian
Placebo Comparator: Placebo
single-dose placebo capsule
single-dose placebo capsule
Through an integration of an fMRI approach coupled with a pharmacological challenge, the goal of the current study will be to investigate the role of dopamine in MDD. Participants in this research will include 36 MDD subjects and 36 demographically matched healthy participants recruited from the community by Dr. Pizzagalli's laboratory at McLean Hospital's Center for Depression, Anxiety and Stress Research. This study will include two sessions:
- The first session will involve a diagnostic interview, and a series of questionnaires and assessments.
- The second session will take place at the McLean Hospital's Neuroimaging Center, and include the administration of a low-dose of amisulpride (50 mg capsule) or placebo, followed by an fMRI brain scan and administration of two behavioral tasks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01253421
|Contact: Aubree A Uhl, BSemail@example.com|
|United States, Massachusetts|
|Belmont, Massachusetts, United States, 02478|
|Contact: Aubree A Uhl, BS 617-855-4237 firstname.lastname@example.org|
|Principal Investigator: Diego A Pizzagalli, PhD|
|Principal Investigator:||Diego A Pizzagalli, PhD||McLean Hospital, Harvard University|